Health

Listeria-based booster improves vaccine’s protection against recurring colon cancer

Credit: Pixabay / CC0 Domain Public

Colourectal, pancreatic, esophageal and colon cancers — some of the most malignant cancers — are more likely to recur where the cancer returns even after successful surgery or radiation therapy.

To treat these cancer-resistant cancers, Thomas Jefferson University researchers under the leadership of Adam Snook, Ph.D., a professor of pharmacology and experimental medicine, instead, use what, in fact, , vaccines to train the patient’s immune system to keep patients healthy. cancer from return. Typically, vaccines use either modified viruses or modified viruses.

Now a new study from Dr. Snook shows in another animal product that the use of antiviral and antiviral methods together is safer and more effective in the fight against cancer than self-treatment.

“Immunization is not unique,” said Dr. Snook, who is also a researcher at the Sidney Kimmel-Jefferson Health Center. “But no one connects them into another combination antibioticshowever when we see the immune response it rises sharply. “

In a previous project, Dr. Snook and his team used a modified form of a virus known as adenovirus as the backbone of cancer treatment that trains patients’ immune systems to detect and and attack a specific cancer cell called GUCY2C (goosey-toosey). ). This vaccine, called Ad5.F35-GUCY2C, is currently in the Phase II clinical trial.

Although the adenovirus-based immune system strongly stimulates the immune response in patients, the effect is short-lived. To create the best possible immune response, antibiotics often require additional doses. However, once introduced, the body becomes accustomed to the adenovirus and as a result does not produce a similar immune response with additional doses. To keep the immune system first pumping out cancer, the body needs a different type of immune system.

Dr. Snook and his team turned to the virus-based immune system using a modified system Listeria monocytogenes which can not cause illness in mice or humans. Unlike the adenovirus platform, the Listeria proximity is not only good at creating an immune response, but also excels at improving the response, even with additional doses.

In addition, “it is extremely effective in inducing a type of antigen called’s antigen that is essential for the development of effective cancer prevention,” said Dr. Snook.

It was then that they came up with the idea of ​​merging the two platforms. When the researchers used the adenovirus vaccine to begin the process of animal immunization and later strengthened it with Listeria-based injection, antibiotics this attack cancer cells shot more than 15 times in the rats.

In a form of recurrent colorectal cancer that has spread to other parts of the body beyond the intestine, the immune system has reduced its frequency and life expectancy in animals, the researchers reported June 23rd in the journal. npj vaccines.

“Combining these two platforms together actually works way, way better than any other platform to create immune response intended for cancer, ”said Dr. Snook.

Also, prevention strategies do not cause poisoning or inflammation in animals indicating that the drug is approved without any side effects.

The results of the study laid the groundwork to investigate for the first time whether this combination could prevent cancer recurrence in patients. The Ministry of Defense recently awarded Dr. Snook, and colleague Babar Bashir, MD, an assistant professor of medicine at Jefferson, awarded the “Group Science” award for taking a collaborative approach to antibiotics in Phase I. clinical trials. Researchers are now working to develop the drug and they expect to start enrolling patients next year.

One-two editions of the combined platform are also effective for other cancers and diseases such as HIV and malaria, where they are effective. prevention strategies were difficult to produce.

“Such a system could work well for these diseases too,” Dr. Snook said.


Small changes make cancer treatment more effective in animal testing


Learn more:
High-Performance Enhancement with Chimeric Adenoviral (Ad5.F35) and Listeria Vectors is a safe and effective strategy for cancer prevention. npj vaccines (2022). DOI: 10.1038 / s41541-022-00483-z

hint: Strengthening the Listeria root enhances immunity against recurrent colon cancer (2022, June 23) Retrieved 23 June 2022 from https://medicalxpress.com/news/2022-06-listeria-based-booster-vaccine -recurring-colon.html

This document is copyrighted. Apart from any genuine transaction for the purpose of investigation or investigation, no part may be reproduced without our written permission. Content is provided for informational purposes only.

Listeria-based booster improves vaccine’s protection against recurring colon cancer Source link Listeria-based booster improves vaccine’s protection against recurring colon cancer

Related Articles

Back to top button